Want to see DE:EUZ full AI Analyst Report?
EUZ Stock Chart & Stats
€13.24
€0.24(1.80%)
At close: 4:00 PM EDT
€13.24
€0.24(1.80%)
Day’s Range― - ―
52-Week Range€11.91 - €17.73
Previous CloseN/A
Volume48.62K
Average Volume (3M)96.41K
Market Cap
€804.70M
Enterprise Value€892.81M
Total Cash (Recent Filing)€110.33M
Total Debt (Recent Filing)€41.04M
Price to Earnings (P/E)16.6
Beta1.32
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.65%
Share Statistics
EPS (TTM)0.80
Shares Outstanding63,515,797
10 Day Avg. Volume102,908
30 Day Avg. Volume96,407
Financial Highlights & Ratios
PEG Ratio0.41
Price to Book (P/B)3.79
Price to Sales (P/S)3.06
P/FCF Ratio27.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€20.87Price Target Upside57.63% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.81
Revenue Forecast (FY)€319.33M
Bulls Say, Bears Say
Bulls Say
Strong ProfitabilityStrong gross, operating, and net margins indicate that the company converts revenue into profit efficiently across its medical technology and isotope activities. Sustained profitability supports internal reinvestment, resilience against operating pressure, and the ability to fund growth without relying heavily on external capital.
Conservative Balance SheetLow leverage gives Eckert & Ziegler meaningful financial flexibility and reduces the burden of debt service during weaker periods. Growing equity and strong returns on that capital indicate a sturdy balance sheet that can support investment, absorb volatility, and preserve strategic options.
Positive Cash GenerationThe company generates substantial operating cash and remains free-cash-flow positive, providing internally generated funding for capital needs and business development. This cash generation complements the low-leverage balance sheet and supports financial resilience over the next several quarters.
Bears Say
Softening Revenue GrowthThe recent TTM revenue decline suggests that the company’s top-line momentum has softened after several years of expansion. If this persists, slower growth could limit operating leverage, reduce the pace of earnings expansion, and make continued margin performance more dependent on execution.
Moderate Cash ConversionCash conversion is below reported earnings, meaning accounting profitability is not fully translating into operating and free cash flow. Over time, this can constrain internally funded investment and make earnings quality more dependent on improvements in working capital or other non-cash items.
Declining Free Cash FlowA roughly 19% TTM decline in free cash flow weakens the company’s financial momentum even though cash generation remains positive. Continued pressure could reduce flexibility for investment, shareholder returns, or strategic initiatives, particularly if revenue growth remains subdued.
Eckert & Ziegler Strahlen und Medizintechnik News
EUZ FAQ
What was Eckert & Ziegler Strahlen- und Medizintechnik AG’s price range in the past 12 months?
Eckert & Ziegler Strahlen- und Medizintechnik AG lowest stock price was €11.91 and its highest was €17.73 in the past 12 months.
What is Eckert & Ziegler Strahlen- und Medizintechnik AG’s market cap?
Eckert & Ziegler Strahlen- und Medizintechnik AG’s market cap is €804.70M.
When is Eckert & Ziegler Strahlen- und Medizintechnik AG’s upcoming earnings report date?
Eckert & Ziegler Strahlen- und Medizintechnik AG’s upcoming earnings report date is Nov 12, 2026 which is in 21 days.
How were Eckert & Ziegler Strahlen- und Medizintechnik AG’s earnings last quarter?
Eckert & Ziegler Strahlen- und Medizintechnik AG released its earnings results on Aug 13, 2026. The company reported €0.192 earnings per share for the quarter.
Is Eckert & Ziegler Strahlen- und Medizintechnik AG overvalued?
According to Wall Street analysts Eckert & Ziegler Strahlen- und Medizintechnik AG’s price is currently Undervalued.
Does Eckert & Ziegler Strahlen- und Medizintechnik AG pay dividends?
Eckert & Ziegler Strahlen- und Medizintechnik AG pays a Annually dividend of €0.22 which represents an annual dividend yield of 1.65%. See more information on Eckert & Ziegler Strahlen- und Medizintechnik AG dividends here
What is Eckert & Ziegler Strahlen- und Medizintechnik AG’s EPS estimate?
Eckert & Ziegler Strahlen- und Medizintechnik AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Eckert & Ziegler Strahlen- und Medizintechnik AG have?
Eckert & Ziegler Strahlen- und Medizintechnik AG has 63,515,797 shares outstanding.
What happened to Eckert & Ziegler Strahlen- und Medizintechnik AG’s price movement after its last earnings report?
Eckert & Ziegler Strahlen- und Medizintechnik AG reported an EPS of €0.192 in its last earnings report. Following the earnings report the stock price went down -0.727%.
Which hedge fund is a major shareholder of Eckert & Ziegler Strahlen- und Medizintechnik AG?
Currently, no hedge funds are holding shares in DE:EUZ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Eckert & Ziegler Strahlen und Medizintechnik Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-21.97%
12-Months-Change
Fundamentals
Return on Equity
19.49%
Trailing 12-Months
Asset Growth
8.04%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Eckert & Ziegler Strahlen- und Medizintechnik AG
Eckert & Ziegler SE manufactures and sells isotope technology components in Europe, North America, Asia, and internationally. It operates through two segments, Medical and Isotope Products. The company provides small implants for the treatment of prostate cancer seeds based on iodine-125; and eye applicators based on ruthenium-106 and iodine-125 for the treatment of choroidal melanomas; brain seed, HDR and brachytherapy; therapeutic and radiotherapy accessories, X-Ray therapy, GA-68 generators, radiochromatography, hot cells; and radiopharmaceuticals, laboratory equipment, radiosynthesis equipment, quality-control equipment, consumables, therapeutic products and plant engineering, and other services. It offers standard and radiation sources for medical and industrial sectors; medical imaging and spect diagnostics, industrial analytical and instrument, high activity CS-137 and CO-60, and oil well logging sources; blood irradiators and environmental disposal source services; and bulk isotopes as well as calibration-related sources for radioisotopes. In addition, the company offers Tc-99m generators and supplies, trade in raw isotopes and other products, and services. It serves medical, scientific, and industrial applications. The company was formerly known as Eckert & Ziegler Strahlen- und Medizintechnik AG and changed its name to Eckert & Ziegler SE in March 2024. Eckert & Ziegler SE was founded in 1992 and is headquartered in Berlin, Germany.
EUZ Stock 12 Month Forecast
Average Price Target
€20.87
▲(57.63% Upside)
Technical Analysis
Gerresheimer
―
MeVis Medical Solutions
―
STRATEC Biomedical
―
Siemens Healthineers AG
―
MagForce AG
―
